Table 2.
Recommended analytical methodology for current and emerging predictive biomarkers for NSCLC
| Biomarker | Type | Analytical techniques |
|---|---|---|
| EGFR ex 18, 19, 21 | Mutation | DNA-SEQ (PCR/NGS) |
| KRAS p.G12C | Mutation | DNA-SEQ (PCR/NGS) |
| ALK | Fusion | IHC & FISH, DNA-SEQ, RNA-SEQ (PCR/NGS) |
| MET exon 14 skipping | Mutation/rearrangement | DNA-SEQ (PCR/NGS)/RNA-SEQ/FISH |
| EGFR ex 20 | Mutation | DNA-SEQ (PCR/NGS) |
| BRAF p.V600E | Mutation | DNA-SEQ (PCR/NGS) |
| ERBB2/HER2 | Mutation | DNA-SEQ (PCR/NGS) |
| RET | Fusion | FISH, DNA-SEQ, RNA-SEQ (PCR/NGS) |
| ROS1 | Fusion | IHC & FISH, DNA-SEQ, RNA-SEQ (PCR/NGS) |
| NRG1 | Fusion | FISH, DNA-SEQ, RNA-SEQ (PCR/NGS) |
| NTRK1, 2, 3 | Fusion | IHC & FISH, DNA- SEQ, RNA-SEQ (PCR/NGS) |
| PD-L1 | Expression | IHC |
ALK anaplastic lymphoma kinase, BRAF B-Raf proto-oncogene, EGFR epidermal growth factor receptor, ERBB2 Erb-B2 receptor tyrosine kinase 2, FISH fluorescent in situ hybridisation, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, KRAS Kirsten rat sarcoma viral oncogene homolog, MET hepatocyte growth factor receptor, NGS next-generation sequencing, NRG1 neuregulin-1, NSCLC non-small cell lung cancer, NTRK neurotrophic tyrosine receptor kinase, PCR polymerase chain reaction, PD-L1 programmed cell death ligand 1, RET rearranged during transfection, ROS1 ROS proto-oncogene 1, SEQ sequencing